Objective: To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection.
Data Sources: Literature was obtained through MEDLINE (1948-November 2011) and International Pharmaceutical Abstracts (1970-October 2011) using the search terms tesamorelin, TH9507, growth hormone releasing factor, and HIV-associated lipodystrophy syndrome. Additional publications were obtained through review of references within primary literature publications as well as pertinent Web sites.
Study Selection And Data Extraction: All articles published in English identified from the data sources were evaluated and all pertinent information was included. All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were included, with a focus on trials completed in humans.
Data Synthesis: In 2 Phase 3 clinical trials and their pooled analyses, tesamorelin was proven to significantly decrease waist circumference and visceral adipose tissue (VAT) following 26 weeks of treatment. Both trials also demonstrated significant improvements in some subjective body image parameters. Both studies had 26-week extension phases that confirmed maintenance of VAT improvements on treatment without adverse impact on blood glucose and lipid parameters. Limited data support off-label uses of tesamorelin at this time.
Conclusions: Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Potential limitations for its use include high cost and lack of long-term safety and adherence data. Tesamorelin provides a useful treatment option for management of patients with significant lipodystrophy related to HIV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1Q629 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of strength training on reducing risk of fractures in people living with Human Immunodeficiency virus.
J Bodyw Mov Ther
March 2025
School of Nursing of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Electronic address:
Article Synopsis
- The study examines how strength training affects fracture risk in HIV-positive individuals, highlighting that ART can lead to decreased bone mineral density and higher fracture risk.
- Sixteen inactive HIV-positive men underwent 12 weeks of strength training, with improvements in femoral neck bone density and reduced fracture risk observed after the program.
- Results indicated a significant reduction in fracture risks (24.79% for major fractures, 72.85% for femoral neck fractures) and an increase in bone and muscle mass, suggesting strength training benefits for this population, although more research is needed.*
Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes.
Biomolecules
November 2024
Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Liebigstraße 20, 04103 Leipzig, Germany.
Serum concentrations of leucine-rich alpha-2 glycoprotein 1 (LRG1) are elevated in several cardio-metabolic and inflammatory diseases. LRG1 also plays an important role in the development of hepatic steatosis and insulin resistance. In lipodystrophies (LDs), severe cardio-metabolic complications can be observed.
View Article and Find Full Text PDFEvidence from clinical studies of leptin: current and future clinical applications in humans.
Metabolism
December 2024
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.
Leptin has been established as the prototype adipose tissue secreted hormone and as a major regulator of several human physiology functions. Here, we are primarily reviewing the findings from studies in humans involving leptin administration. We are describing the metabolic, endocrine and immunologic effects of leptin replacement in conditions of leptin deficiency, such as short-term fasting in healthy individuals, relative energy deficiency in sports (REDS), congenital leptin deficiency (CLD), generalized (GL) and partial lipodystrophy (PL), HIV-associated lipodystrophy (HIV-L) and of leptin treatment in conditions of leptin excess (common obesity, type 2 diabetes, steatotic liver disease).
View Article and Find Full Text PDFCorrelation of APOE polymorphism, expression, and plasma levels with cardiac comorbidities among lipodystrophy in HIV-infected patients.
Clin Chim Acta
January 2025
Department of Molecular Biology, National AIDS Research Institute Pune 411026, India. Electronic address:
Article Synopsis
- - The study examined the impact of ApoE gene polymorphisms on HIV-related lipodystrophy (HIVLD) and metabolic abnormalities in 200 HIV-infected patients, revealing that certain genotypes might influence the risk of developing these conditions.
- - Results indicated that ApoE alleles 2 and specific genotypes, like 4/4, were connected to a decreased risk of HIV-1 infection and a lower likelihood of severe HIVLD, whereas allele 2 was linked to increased risk of both HIV acquisition and HIVLD severity.
- - Additionally, the study found correlations between specific ApoE genotypes and impaired cholesterol and glucose levels in patients without HIVLD, highlighting the intricate relationship between genetics and metabolic health in the context
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy.
Expert Opin Drug Metab Toxicol
September 2024
Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Article Synopsis
- - The introduction of antiretroviral therapy (ART) has greatly improved the lives of individuals with HIV, but it can lead to significant side effects, particularly cardiometabolic complications, especially in children and adolescents.
- - A literature review was conducted to gather current knowledge on metabolic issues (like dyslipidemia and insulin resistance) and diseases (such as prediabetes and cardiovascular diseases) linked to ART in the pediatric population with HIV.
- - Close monitoring of these metabolic complications is crucial as they heighten the risk of developing serious health conditions later in life. Addressing these challenges requires better access to treatments, technology advancements, and a focus on reducing healthcare disparities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!